Josh Showalter1, Nghia D Nguyen1, Samer Baba1, Chi Hyun Lee2, Jing Ning2, Kimberly Klein1, M Amer Wahed1, Ashok Tholpady3. 1. Department of Pathology and Laboratory Medicine, The University of Texas McGovern Medical School at Houston, Houston, TX, USA. 2. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND: Patients with heart failure often have concomitant renal disease which can result in uremic platelet dysfunction. Determining whether uremia has affected platelets by platelet aggregometry can be challenging in these patients since they are often on antiplatelet medications. This study was undertaken to determine if platelet aggregation studies could identify heart failure patients at risk for uremic bleeding prior to cardiac surgery. METHODS: Platelet aggregation studies from three groups were studied and compared: 17 heart failure patients with mild to moderate renal impairment, 17 heart failure patients without renal abnormalities and 17 healthy volunteers. RESULTS: Platelet aggregation was severely impaired in both heart failure groups with and without renal abnormalities compared to healthy controls, and there were no significant differences in platelet aggregation in response to any of the agonists. There was a pan-decrease in platelet aggregation to all agonists in all heart failure patients. CONCLUSION: Platelet aggregometry does not appear to be useful in measuring platelet dysfunction in heart failure patients with mild to moderate renal impairment.
BACKGROUND:Patients with heart failure often have concomitant renal disease which can result in uremic platelet dysfunction. Determining whether uremia has affected platelets by platelet aggregometry can be challenging in these patients since they are often on antiplatelet medications. This study was undertaken to determine if platelet aggregation studies could identify heart failurepatients at risk for uremic bleeding prior to cardiac surgery. METHODS:Platelet aggregation studies from three groups were studied and compared: 17 heart failurepatients with mild to moderate renal impairment, 17 heart failurepatients without renal abnormalities and 17 healthy volunteers. RESULTS:Platelet aggregation was severely impaired in both heart failure groups with and without renal abnormalities compared to healthy controls, and there were no significant differences in platelet aggregation in response to any of the agonists. There was a pan-decrease in platelet aggregation to all agonists in all heart failurepatients. CONCLUSION: Platelet aggregometry does not appear to be useful in measuring platelet dysfunction in heart failurepatients with mild to moderate renal impairment.
Authors: Luisa R de Meirelles; Angela de C Resende; Cristiane Matsuura; Angelo Salgado; Natalia R Pereira; Pedro G Cascarelli; Antônio C Mendes-Ribeiro; Tatiana M C Brunini Journal: Clin Exp Pharmacol Physiol Date: 2011-10 Impact factor: 2.557
Authors: Philipp Opfermann; Alessia Felli; Christine Schlömmer; Martin Dworschak; Michele Bevilacqua; Mohamed Mouhieddine; Daniel Zimpfer; Andreas Zuckermann; Barbara Steinlechner Journal: Front Med (Lausanne) Date: 2022-02-25